Recombinant expression vector applicable to rapid screening for recombinant strain and application
US-12037632-B2 · Jul 16, 2024 · US
US10119129B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10119129-B2 |
| Application number | US-201013318850-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 7, 2010 |
| Priority date | May 7, 2009 |
| Publication date | Nov 6, 2018 |
| Grant date | Nov 6, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to an improved enzyme complex having a plurality of enzyme activities of an expression product obtained by fermentation of the genus Trichoderma in combination with one or more enzymes of a different fungus strain.
Opening claim text (preview).
The invention claimed is: 1. An enzyme complex having beta-1,4-endoglucan hydrolase activity comprising: a. a fermentation product of Trichoderma reesei wherein at least 61 % of the beta-1,4-endoglucan hydrolase activity of the enzyme complex, as measured by the “Assay 1” method, is from the fermentation product of Trichoderma reesei; and b. one or more enzymes derived from Penicillium funiculosum selected from a xylanase (EC 3.2.1.8), a cellulase (EC 3.2.1.4), and a beta-glucanase (EC 3.2.1.6), wherein 30% to 39% of the beta-1,4-endoglucan hydrolase activity of the enzyme complex, as measured by the “Assay 1” method, is from a fermentation product of Penicillium funiculosum; wherein the enzyme complex is substantially cell free. 2. The enzyme complex according to claim 1 , wherein said one or more enzymes derived from Penicillium funiculosum is an expression product obtained by fermentation of said Penicillium funiculosum. 3. The enzyme complex according to claim 2 , which expression product obtained by fermentation of said Penicillium funiculosum comprises a xylanase. 4. The enzyme complex according to claim 1 , further comprising one or more enzyme activities selected from the list consisting of endo-1,4-β-xylanase, endo-1,3(4)-β-glucanase, cellulase, laminarinase, endo-1,5-α-L arabinanase, beta-D-glucoside glucohydrolase, β-Xylosidase, cellobiohydrolase, glucan 1,4-beta-glucosidase, xyloglucan-specific exo-beta-1,4-glucanase and α-N Arabinofuranosidase. 5. An enzyme complex having beta-1,4-endoglucan hydrolase activity comprising: a. a first expression product obtained by fermentation of Trichoderma reesei , wherein the first expression product accounts for at least 61% of the beta-1,4-endoglucan hydrolase activity of the enzyme complex; and b. a second expression product obtained by fermentation of Penicillium funiculosum, wherein the second expression product accounts for at least 39% of the beta-1,4-endoglucan hydrolase activity of the enzyme complex; wherein the percentages of beta-1,4-endoglucan hydrolase activity are measured by the “Assay 1” method; wherein the enzyme complex is substantially cell free. 6. The enzyme complex according to claim 1 , wherein said strain is Trichoderma reesei deposited under the Budapest treaty in the American Type Culture Collection (ATCC) having a strain designation GC Cellulose A83 GICC 0004, M03000004 deposited by Danisco A/S on the date of 5 May 2009, or a derivative or progeny thereof. 7. The enzyme complex according to claim 2 , wherein said expression product obtained by fermentation of a Penicillium fungus is from single culture of the species Penicillium funiculosum. 8. The enzyme complex according to claim 7 , wherein said strain is Penicillium funiculosum deposited under the Budapest treaty in the International Mycological Institute under the number IMI 378536, or a derivative or progeny thereof. 9. The enzyme complex according to claim 1 , wherein said expression product obtained by fermentation is from a wild type species. 10. The enzyme complex according to claim 1 , having an enzyme activity of at least about 3000 U/g, such as at least about 4000 U/g, such as at least about 5000 U/g, such as at least about 6000 U/g, such as at least about 7000 U/g as measured by “Assay 1” as described herein derived from fermentation of Trichoderma reesei. 11. The enzyme complex according to claim 1 , having a total enzyme activity of at least about 4000 U/g as measured by “Assay 1”as described herein. 12. The enzyme complex according to claim 1 , wherein about 2362 U/g beta-1,4-endoglucan hydrolase activity is from a fermentation product of Penicillium funiculosum and wherein about 5315 u/g U/g beta-1,4-endoglucan hydrolase activity is from a fermentation product of Trichoderma reesei wherein said units/g (U/g) is determined by “Assay1”. 13. The enzyme complex according to claim 1 , wherein said enzyme complex contains at least 5 different side activities. 14. The enzyme complex of claim 1 or claim 5 further comprising at least one preservative.
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Antineoplastic agents · CPC title
for joint disorders, e.g. arthritis, arthrosis · CPC title
Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150) · CPC title
Endo-1,4-beta-xylanase (3.2.1.8) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.